The in vitro susceptibility to acyclovir of 204 herpes simplex virus isolates from 165 immunocompromised patients treated at our hospital was determined by the cytopathic effect reduction assay. Approximately 95% of herpes simplex virus 1 and 73% of herpes simplex virus 2 isolates were inhibited by acyclovir at concentrations of !2 mg/mL. From 8 patients (5%), an isolate with low susceptibility to acyclovir (50% inhibitory dose, 13 mg/mL) was recovered. Medical records of 83 patients were reviewed. Lesions resolved in most of the patients, independent of treatment. Treatment failures were not always associated with isolation of an in vitro-resistant virus. On the contrary, when a virus with low susceptibility to acyclovir was isolated, resolution of the lesion was the rule. In 9 of 10 patients with subsequent recurrent episodes of disease, the susceptibility of the viruses isolated was similar to that of the first episode. Routine susceptibility testing in our geographic area is not encouraged because of the low incidence of acyclovir-resistant herpes simplex viruses.
Infections caused by herpes simplex virus (HSV) are a major cause of morbidity in immunosuppressed hosts, such as patients who are positive for HIV or are undergoing organ transplantation. Acyclovir (Acv) is the drug of choice for treatment of these patients. Administered orally or intravenously, it decreases pain and viral shedding and accelerates healing [1] . Topical therapy can also be useful for these patients, although it is not as effective [2] . Mucocutaneous HSV infections are usually self-limited in the immunocompetent host. Because immunosuppressed patients cannot depend on their immune system to eliminate the virus, infection can result in extensive and persistent ulcerative disease with continuous viral shedding and lack of response to prolonged Acv therapy; strains of HSV that are less susceptible or resistant to Acv have occasionally been recovered from these patients [3] . Otherwise, in immunocompromised patients who receive Acv for the management of acute HSV disease, the incidence of resistance is extremely low. In addition, Acv-resistant strains of HSV have rarely been isolated from immunocompetent patients [4] .
The use of susceptibility testing could help improve the management of patients with herpesvirus disease who are unresponsive to standard regimens of Acv. Patients whose lesions persist or worsen while they are receiving Acv therapy could benefit from susceptibility studies. In such cases, knowledge of a strain's in vitro susceptibility to Acv would be useful for the selection of alternative antiviral therapy [5] [6] [7] , which might involve increasing the dose of oral Acv or changing to high-dose continuous infusion of Acv (for those patients who do not respond to standard regimens of Acv) [8, 9] . To determine the susceptibility of HSV to Acv, various tests have been designed. The most frequently used tests are the plaque reduction assay (PRA), the viral cytopathic effect reduction assay (CRA), the dye-uptake method (DUA), and the DNA hybridization assay.
There is no consensus regarding the level of in vitro susceptibility that indicates a drug-resistant virus, but many different types of assays have shown that Acv-resistant isolates are usually susceptible to an Acv concentration of 12-3 mg/mL [10] [11] [12] . Nevertheless, correlation between clinical findings and in vitro susceptibility to Acv has not been definitely established, and further studies are needed. The present article reports the results of susceptibility testing of HSV isolates from immunocompromised patients who attended in a university tertiary-care hospital and provides further data on the clinical correlates to the in vitro results.
PATIENTS, MATERIALS, AND METHODS

Patients and virus isolation techniques.
A total of 204 isolates (131 HSV-1 isolates and 73 HSV-2 isolates) were recovered from 165 immunosuppressed patients (89 patients who had AIDS, 18 who had hematological malignancies, 20 who had received heart transplants, 8 who had received bone marrow transplants, 14 who were receiving corticoid therapy, 10 who had neoplastic disease, 4 who had received kidney transplants, 1 who had common variable hypogammaglobulinemia, and 1 who had diabetes). HSV strains were isolated from 178 mucocutaneous lesions (70 oral, 4 pharyngeal, 8 nasal, 16 labial, 25 genital, 34 anal, and 21 cutaneous exudates), 19 specimens of bronchoalveolar lavage [BAL] fluid, 4 esophageal biopsy specimens, 1 brain biopsy specimen, 1 rectal biopsy specimen, and 1 urine specimen. For isolation of HSV, specimens for culture were routinely obtained by swabbing the base of mucosal or cutaneous ulcers. The swabs or specimens were placed in transport medium and inoculated on cell monolayers, usually Vero or HeLa cells. BAL fluid and biopsy specimens were transported to the laboratory without use of transport medium. If 2 specimens were available for the same episode of disease, both were used.
Virus isolation, identification, and typing (with use of the Microtrak HSV-1/HSV-2 culture confirmation/typing test; Syva) were performed by using conventional techniques [13] . Viruses were then passaged in Vero cells to produce a working stock with a known titer [14] and were stored at Ϫ80ЊC until susceptibility tests were performed.
Cytopathic effect reduction assay. In vitro susceptibility of HSV isolates to Acv was determined by the cytopathic effect reduction assay, performed in 96-well plates. In summary, Vero cells were cultured and maintained in Eagle's minimum essential medium supplemented with nonessential amino acids, lglutamine, and fetal calf serum. Cell cultures were infected with ∼100 TCID 50 (range, 31.6-316 TCID 50 ) of each virus, and serial 2-fold dilutions of Acv (range, 0.02-50 mg/mL) were added to the wells. After incubation for 72 h, the cytopathic effect of each strain was recorded and scored as positive or negative. We considered a well result to be positive if there was у1 focal lesion of cytopathic effect. The Kärber method [15] was used to determine the drug concentration causing a 50% reduction in viral cytopathic effect, or 50% inhibitory dose (ID 50 ) and the 90% inhibitory dose (ID 90 ) of Acv-that is, the dilution at which 50% or 90% of the inoculated cultures had negative results. The results are expressed as micrograms per milliliter [16] .
One resistant strain derived by repeated passage in the presence of Acv was introduced in the study as a control (kindly provided by Dr. F. Salmeró n, Centro Nacional de Microbiología, Virología e Inmunología Sanitarias de Majadahonda, Spain). Control wells that exclusively contained either cells with virus or the higher concentration of Acv (50 mg/mL) were included in each assay. Of the 165 patients, medical records were available for 83, who had a total of 96 episodes of HSV disease. Treatment and evolution of the lesions were reviewed.
RESULTS
Antiviral susceptibility.
The in vitro Acv susceptibilities of 204 HSV clinical isolates recovered from 165 patients were determined. The median ID 50 of Acv for HSV-1 was 0.615 mg/ mL (range, 0.050-4.456 mg/mL). For HSV-2, the median ID 50 was 1.698 mg/mL (range, 0.472-5.296 mg/mL).
Approximately 86% of HSV-1 isolates were inhibited by Acv concentrations of !1 mg/mL, and 195% were inhibited by concentrations of !2 mg/mL. A total of 73% of HSV-2 isolates were inhibited by Acv concentrations of !2 mg/mL. Of 204 virus strains studied, 9 (4%; 1 strain of HSV-1 and 8 strains of HSV-2) showed susceptibility to Acv at an ID 50 of 13 mg/mL.
Although a wide spectrum of susceptibilities was found among the HSV strains studied, none of the strains had ID 50 values of Acv comparable to that of the resistant control strain (ID 50 , 12.559 mg/mL). For 6 patients from whom 2 strains were recovered from the same episode of disease, the Acv ID 50 values were very similar (table 1). All the strains isolated from lesions other than mucocutaneous lesions had Acv ID 50 values of !3 mg/mL.
Clinical response. We recorded data on the treatment and evolution of 96 episodes of HSV disease in 83 patients. Acv therapy was administered for 90 episodes. In 46 cases, the treatment was oral; in 15 cases, intravenous; and, in 11 cases, topical. In 18 cases, the route of administration was combined (oral and/or intravenous and/or topical). The lesions resolved in 84 cases. For 6 patients, lesions did not resolve, despite antiviral therapy. Four of these patients had incomplete treatment and died of their disease within a few days (1 had received a bone marrow transplant, 2 had lymphoma, and 1 had AIDS); these patients were excluded from the analysis. The other 2 patients received prolonged treatment, and their lesions improved but did not heal completely. HSV isolates recovered from these lesions were susceptible to Acv (ID 50 , 0.941 and 1.330 mg/mL). Both patients died 1-4 months later, because of the natural progression of their disease (AIDS). Six patients received no antiviral treatment and their lesions resolved spontaneously. Of 79 patients with data available for analysis, 2 (patients 5 and 45) had persistence of lesions and failure to eradicate the virus, and they were followed for 2.5 and 1.5 months, respectively. The lesions of patient 5 responded to Acv when treatment was initiated, and the lesions of patient 45 responded to Acv when the doses were increased. For these 2 patients, the in vitro susceptibility of HSV isolated at different times and from different sites, the treatment administered, and the evolution of the episodes of disease are shown in Recurrences of disease after therapy. There were 15 recurrences in 10 patients (the episodes of disease were separated by 0.5-23 months). Of 27 strains of HSV isolated, only 1 had an elevated Acv ID 50 (table 4). Patient 41 had 4 episodes during the study period; in the third episode, a resistant HSV-2 strain was isolated, and, 50 days after that episode resolved without treatment, a susceptible HSV strain was isolated.
DISCUSSION
The clinical development of antiviral drug resistance has been increasingly reported for infections caused by HSV [17] . One of the main problems in testing for in vitro susceptibility is that antiviral studies are not well standardized. To determine the Acv susceptibility of HSV, various tests have been designed, such as the PRA, the CRA, the DUA, and the DNA hybridization assay.
ID 50 values obtained by the hybridization method correlate well with values obtained by the PRA [18] . The DUA yields ID 50 values that are 5-10-fold higher than the values determined by the PRA [10] . Testing of a single virus strain by these different assays may produce different results. Variables that affect the results obtained by each of the assays include the inoculum effect, the media used, and the conditions of incubation [19] . Even with a single type of assay, results are extremely dependent on the origin of the cell culture used [20] . In the case of Acv, intracellular levels of endogenous thymidine may be responsible for such differences [21] .
PRA has been considered by some investigators to be the reference method for in vitro study of susceptibility to antivirals, but the fact that HSV is a rapidly growing virus and has a clear-cut cell-killing effect allows for the use of easier methods for the study of these viruses. The CRA was introduced by Ho and Enders [22] for the in vitro study of the susceptibility of cells to interferon. De Clercq et al. [23] and DeClerq [24] used the CRA to study the susceptibility of HSV to antivirals. The addition of the vital dye neutral red to the drug-treated, virusinfected cultures permits automated reading. This method was named the "dye-uptake method." McLaren et al. [25] adapted the DUA method for the study of HSV susceptibility to acyclovir. The DUA is equivalent to the CRA, the only difference being the reading method, and the ID 50 values determined by the CRA and the DUA are comparable, if the optimal conditions for both assays are applied [26] . In our study, we used the CRA, with Vero cells, to test all isolates. This assay is based on measurements of the inhibition of the cytopathic effect and provides a simple determination of Acv susceptibility [27] . Using this assay, we found that repeated testing of several specimens of the same lesion revealed similar susceptibilities (table 1), which indicates that the assay has an acceptable degree of reproducibility.
Our results show that the mean ID 50 value for HSV-1 (0.615 mg/mL) is almost 3 times lower than that for HSV-2 (1.698 mg/ mL). These differences and the overlapping of values for the 2 types of viruses confirm previous observations [27] [28] [29] [30] .
There is no consensus of opinion regarding which level of in vitro susceptibility indicates a resistant virus, but most investigators agree that Acv-resistant isolates are usually susceptible to Acv concentrations of 12 mg/mL. However, Chatis and Crumpacker [31] pointed out that an Acv ID 50 value of 12 mg/ mL is unusually high for the definition of resistance to Acv, and use of this value could underestimate the real incidence of resistance. We detected 26 HSV strains (6 HSV-1 strains and 20 HSV-2 strains)-or 13% of the strains isolated-that had Acv ID 50 values of 12 mg/mL. Swierkosz and Biron [32] proposed that when the DUA is used to study susceptibility, the ID 50 value denoting resistance would be 13 mg/mL. In our study, 9 (4%) of 204 virus strains studied (recovered from 5% of the patients), were resistant at Acv ID 50 values of 3 mg/mL.
It should be noted that, although a low susceptibility to Acv in vitro was detected in the HSV strains in our study, resistance did not seem to be the major cause of treatment failure, because other factors, such as the patient's immunologic status, may have contributed to the poor clinical response. Medical records were available for 10 patients infected with strains of HSV for which the Acv ID 50 was 12 mg/mL at presentation. The lesions of all of these 10 patients resolved, with or without Acv treatment (table 3) .
On the other hand, persistence of lesions in spite of therapy was unrelated to the Acv ID 50 of the infecting strain. Testing results for the 2 patients (patients 45 and 5) whose lesions persisted and then finally resolved (table 2) show that all isolates were susceptible to Acv. Patient 45 received a standard regimen of Acv, and the HSV isolate was susceptible in vitro. During treatment, a new lesion appeared at another site (probably because of autoinoculation), and, from this lesion, we were also able to isolate a strain of HSV that was susceptible to Acv. The lesions resolved completely after treatment with higher doses of Acv. In patient 5, the lesion did not resolve until the patient received Acv (table 2) .
HSV infections are usually mild and self-limited. Cell-mediated immunity plays a significant role in the eradication of HSV disease. The great variability in the abilities of immunosuppressed patients to control viral infections is a major confounding factor in efficacy testing of any antiviral therapy. Favorable responses were observed in most of our patients regardless of therapy. Six episodes of disease resolved without treatment. Moreover, in the 3 episodes for which the HSV isolates were susceptible at Acv ID 50 values of 13 mg/mL and for which the patients were treated with Acv, the lesions resolved with the use of standard regimens of the antiviral agent, a result that reinforces the finding that most HSV infections are self-limited, independent of therapy.
Refractory disease due to HSV in these patients could be related to circumstances other than in vitro susceptibility. The description of HSV as resistant at Acv ID 50 values of 13 mg/ mL is probably appropriate, on the basis of multiple studies [32] [33] [34] [35] [36] , other factors, such as incomplete adherence to therapy, poor absorption of the drug, and interaction between drugs, should be taken into account before resistance to antiviral therapy is suspected.
After primary infection, HSV remains latent in the organism for life, and, from time to time, the virus reactivates and produces a recurrent disease. Recurrences probably reflect the virus that caused the primary infection [19] . During follow-up, a total of 15 recurrences of disease were recorded. All but 1 of the HSV isolates were clearly susceptible to Acv in vitro, a finding that shows that the appearance of resistance is very infrequent when Acv is used at standard dosages to manage acute infections.
To summarize, in 5% of the patients in our study (4 of 83),
we detected a strain of HSV with low susceptibility to Acv in vitro (ID 50 , 13 mg/mL). The results of CRA had a close correlation with the clinical responses in our patients; 97.5% of lesions that yielded strains of HSV that became susceptible at an Acv ID 50 of !3 mg/mL resolved with Acv treatment. For 2 patients, CRA results were unable to predict treatment failure. The immunologic status of these 2 patients (end-stage AIDS) may have played a significant role in the persistence of the lesions. In our experience, there is no need to routinely test HSV isolates for susceptibility to Acv. Determination of the susceptibilities of strains of HSV should be indicated only for viruses isolated from patients who have severe immunologic disturbance and lesions that persist or worsen while they are receiving Acv therapy.
